World Health Organization expert groups recommend that candidate vaccines and treatments for the Bundibugyo virus be used only within clinical trials [1].
This restriction ensures that medical interventions are evaluated through rigorous data collection during an active outbreak. Without controlled trials, public health officials cannot determine the safety or efficacy of new therapeutics for this specific strain of Ebola [2].
On Tuesday, May 19, the WHO convened advisory panels to assess the current landscape of candidate vaccines and therapeutics [3]. The experts focused on the Bundibugyo virus, which is causing an outbreak in the Ituri province of the eastern Democratic Republic of Congo [3]. Cases have also been reported in Uganda [3].
The scale of the current crisis underscores the urgency of the WHO's review. There have been more than 300 suspected cases [4] and at least 88 deaths [4] associated with the outbreak. The virus continues to challenge regional health systems, making the development of a verified vaccine a primary goal for international health agencies [2].
By limiting the use of these candidates to clinical trials, the WHO aims to generate robust data to guide the broader public health response [2]. This approach prevents the premature deployment of unproven medicines while accelerating the search for a viable cure [1].
The advisory groups said there is a need for coordinated efforts between the Democratic Republic of Congo, Uganda, and international researchers to monitor the spread of the virus [3]. The WHO continues to monitor the situation in the Ituri province as the clinical trials proceed [3].
“candidate vaccines and treatments for the Bundibugyo virus be used only within clinical trials”
The WHO's decision to restrict candidate treatments to clinical trials indicates that there is currently no globally approved, standard-of-care vaccine or therapeutic specifically for the Bundibugyo virus. By prioritizing data over immediate, widespread deployment, the organization is attempting to avoid the risks of ineffective treatments while establishing a scientific baseline for future outbreaks of this specific Ebola strain.
